Table 1.
Patient characteristics at baseline
| All (n = 47) | Exacerbated (n = 20) | Non-Exacerbated (n = 27) | |
|---|---|---|---|
| Age, y (SD) | 30.7 (10.4) | 27.9 (8.9) | 32.7 (11.0) |
| BMI, kg/m2 (SD) | 20.4 (3.8) | 18.5 (3.5)* | 21.8 (3.5) |
| Sex | |||
| Female, n (%) | 20 (43) | 9 (45) | 11 (41) |
| Male, n (%) | 27 (57) | 11 (55) | 16 (59) |
| Genotype | |||
| F508del homozygous, n (%) | 23 (49) | 11 (55) | 12 (45) |
| F508del heterozygous, n (%) | 16 (34) | 7 (35) | 9 (33) |
| Other, n (%) | 8 (17) | 2 (10) | 6 (22) |
| FEV1, L (SD) | 1.48 (0.69) | 1.11 (0.39)* | 1.74 (0.74) |
| FEV1, % predicted (SD) | 38.0 (15.5) | 28.4 (7.9)* | 45.2 (15.9) |
| FVC, L (SD) | 2.32 (1.06) | 1.76 (0.59)* | 2.72 (1.15) |
| FVC, % predicted (SD) | 50.0 (17.1) | 38.7 (9.0)* | 57.9 (17.1) |
| Leucocyte, 10^9/l (SD) | 8.9 (3.1) | 10.9 (3.0)* | 7.5 (2.2) |
| CRP, mg/dl (SD) | 3.5 (5.3) | 6.9 (6.7)* | 1.0 (0.8) |
| Pancreatic insufficiency, n (%) | 43 (91) | 18 (90) | 25 (93) |
| P. aeruginosa positive, n (%) | 33 (70) | 13 (65) | 20 (74) |
| Cystic fibrosis-related diabetes, n (%) | 16 (34) | 7 (35) | 9 (33) |
| O2-Supplementation, n (%) | 21 (45) | 14 (70)* | 7 (26) |
| NIV, n (%) | 7 (15) | 6 (30)* | 1 (4) |
| tVitaLog (days) (SD) | 6.4 (3.7) | 7.6 (4.1) | 5.5 (3.2) |
NIV: non invasive ventilation
*p < 0.05 between subgroups